Send to

Choose Destination
Parkinsonism Relat Disord. 2007 Dec;13(8):532-4. Epub 2007 Mar 26.

Botulinum toxin A for drooling in Parkinson's disease: a pilot study to compare submandibular to parotid gland injections.

Author information

Department of Allied Health Occupations, Speech Language Therapy, Radboud University Nijmegen Medical Centre, The Netherlands.


Drooling is a common and incapacitating problem in Parkinson's disease (PD). Treatment with botulinum neurotoxin (BoNT) into the parotid glands seems beneficial. Injection of the submandibular glands may also be effective since these produce 70% of the daily unstimulated saliva. We randomly allocated patients to BoNT injections into the submandibular glands or the parotid glands. Within-group improvements were significant for the submandibular group, but not for the parotid group. Between-group differences showed a trend towards superiority for the submandibular group. Injecting the submandibular glands instead of the parotid glands seems a promising approach, and larger studies are justified.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center